Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Cited In for PubMed (Select 22198468)

1.

Advances in Statistical Approaches Oncology Drug Development.

Ivanova A, Rosner GL, Marchenko O, Parke T, Perevozskaya I, Wang Y.

Ther Innov Regul Sci. 2014 Jan;48(1):81-89.

2.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24.

PMID:
25443274
3.

Autocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers.

Vadnais C, Shooshtarizadeh P, Rajadurai CV, Lesurf R, Hulea L, Davoudi S, Cadieux C, Hallett M, Park M, Nepveu A.

Biol Open. 2014 Sep 12;3(10):937-46. doi: 10.1242/bio.20148193.

4.

Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.

Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, Thiery JP.

EMBO Mol Med. 2014 Sep 11;6(10):1279-93. doi: 10.15252/emmm.201404208.

5.

Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.

Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton T, Hunt KK.

Ann Surg. 2014 Oct;260(4):608-14; discussion 614-6. doi: 10.1097/SLA.0000000000000924.

PMID:
25203877
6.

Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE.

BMC Womens Health. 2014 Aug 29;14:102. doi: 10.1186/1472-6874-14-102.

7.

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.

Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, Muss HB.

Oncologist. 2014 Oct;19(10):1076-83. doi: 10.1634/theoncologist.2014-0184. Epub 2014 Aug 20.

8.

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.

Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J.

J Natl Cancer Inst. 2014 Aug 19;106(8). pii: dju152. doi: 10.1093/jnci/dju152. Print 2014 Aug.

9.

GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2).

Sizemore GM, Sizemore ST, Seachrist DD, Keri RA.

J Biol Chem. 2014 Aug 29;289(35):24102-13. doi: 10.1074/jbc.M114.593582. Epub 2014 Jul 10.

PMID:
25012653
10.

MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.

Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, Gray NS, Mitchison TJ, Zhao JJ.

Elife. 2014 May 20;3:e01763. doi: 10.7554/eLife.01763.

11.

Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S.

Lancet Oncol. 2014 May;15(6):e234-42. doi: 10.1016/S1470-2045(13)70598-9.

12.

Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.

Davis SL, Eckhardt SG, Tentler JJ, Diamond JR.

Ther Adv Med Oncol. 2014 May;6(3):88-100. doi: 10.1177/1758834013519843. Review.

13.

Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).

Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ.

Ann Surg Oncol. 2014 Sep;21(9):2889-96. doi: 10.1245/s10434-014-3721-7. Epub 2014 May 1.

14.

Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).

Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A; I-SPY1 Investigators.

Cancer Med. 2014 Jun;3(3):693-701. doi: 10.1002/cam4.235. Epub 2014 Apr 9.

15.

Genomic profiling in luminal breast cancer.

Gluz O, Hofmann D, Würstlein R, Liedtke C, Nitz U, Harbeck N.

Breast Care (Basel). 2013 Dec;8(6):414-22. doi: 10.1159/000357535. Review.

16.

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ.

Cancer Cell. 2014 Feb 10;25(2):152-65. doi: 10.1016/j.ccr.2014.01.009.

17.

Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.

Wolf DM, Lenburg ME, Yau C, Boudreau A, van 't Veer LJ.

PLoS One. 2014 Feb 7;9(2):e88309. doi: 10.1371/journal.pone.0088309. eCollection 2014.

18.

LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer.

Lovat F, Ishii H, Schiappacassi M, Fassan M, Barbareschi M, Galligioni E, Gasparini P, Baldassarre G, Croce CM, Vecchione A.

Oncotarget. 2014 Feb 28;5(4):970-7.

19.

Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

Eroglu Z, Tagawa T, Somlo G.

Oncologist. 2014 Feb;19(2):135-50. doi: 10.1634/theoncologist.2013-0283. Epub 2014 Jan 16. Review.

20.

Breast Cancer Biomarkers: Utility in Clinical Practice.

Le Du F, Ueno NT, Gonzalez-Angulo AM.

Curr Breast Cancer Rep. 2013 Dec;5(4). doi: 10.1007/s12609-013-0125-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk